| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
07-12-2016, 12:39 PM
|
#1 | ||
|
|||
|
Member
|
This is great news folks!
Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s Posted by Maggie McGuire Kuhl, July 12, 2016 A promising therapy that may slow or stop Parkinson’s progression is moving forward. Today The Michael J. Fox Foundation (MJFF), the Van Andel Research Institute (VARI) in Michigan and the Cure Parkinson’s Trust (CPT) in the United Kingdom announced plans to collaborate to assess the clinical use and development of cancer drug nilotinib. The program includes the goal of planning of a double-blind, placebo-controlled clinical trial of nilotinib, which MJFF hopes can begin in 2017. Parkinson's Disease | Nilotinib Update: Where We Stand with a Cancer Drug for Parkinson’s Last edited by zanpar321; 07-12-2016 at 02:39 PM. Reason: Adding new text |
||
|
 Reply With Quote
|
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| Michael J. Fox Foundation Partners with Charles River Laboratories on Parkinson’s Res | Parkinson's Disease | |||
| NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
| NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development o | Parkinson's Disease | |||
| ALS Therapy Development Institute Partners with Clinical Centers to Establish Patholo | ALS News & Research | |||
Michael Fox Partners to Assess Clinical Development of Nilotinib in Parkinson's
Threaded Mode